A5064961032- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Photodynamic Therapy Research Studies
- HER2/EGFR in Cancer Research
- Nanoplatforms for cancer theranostics
- Chronic Lymphocytic Leukemia Research
- Nonmelanoma Skin Cancer Studies
- CAR-T cell therapy research
- Porphyrin and Phthalocyanine Chemistry
- Medical Imaging Techniques and Applications
- Lung Cancer Treatments and Mutations
- MRI in cancer diagnosis
- PARP inhibition in cancer therapy
- Prostate Cancer Treatment and Research
- Acute Myeloid Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Radiation Therapy and Dosimetry
- Neuroendocrine Tumor Research Advances
- Immune Cell Function and Interaction
- Infectious Diseases and Mycology
- Advanced Radiotherapy Techniques
- Radiomics and Machine Learning in Medical Imaging
- Peptidase Inhibition and Analysis
- Photocathodes and Microchannel Plates
Nordic Nanovector (Norway)
2016-2023
Oslo University Hospital
2009-2013
Norwegian Cancer Society
1994-1997
Abstract— Microscopic fluorescence photometry incorporating a light‐sensitive thermo‐electrically cooled charge‐coupled device (CCD) camera was employed to investigate the distribution of 5‐aminolevulinic acid (ALA)‐induced porphyrins in 22 patients with total number 52 noduloul‐cerative basal cell carcinomas (BCC) after topical ALA application or without dimethylsulfoxide (DMSO)/ethylenediaminetetraacetic (EDTA) intravenous administration ALA. Both localization patterns and amounts...
The aim of the present study was to explore biodistribution, normal tissue toxicity, and therapeutic efficacy internalizing low-dose rate alpha-particle-emitting radioimmunoconjugate 227Th-trastuzumab in mice with HER2-expressing breast cancer xenografts. Biodistribution 227Th-rituximab nude bearing SKBR-3 xenografts were determined at different time points after injection. Tumor growth measured administration 227Th-trastuzumab, 227Th-rituximab, cold trastuzumab, saline. toxicity evaluated...
Background The aim of this study was to investigate therapeutic efficacy and normal tissue toxicity single dosage fractionated targeted alpha therapy (TAT) in mice with HER2-expressing breast ovarian cancer xenografts using the low dose rate radioimmunoconjugate 227Th-DOTA-p-benzyl-trastuzumab. Methodology/Principal Findings Nude carrying HER2-overexpressing subcutaneous SKOV-3 or SKBR-3 were treated 1000 kBq/kg 227Th-trastuzumab as injection four injections 250 intervals 4–5 days, 2 weeks,...
Relapse of chronic lymphocytic leukaemia and non-Hodgkin's lymphoma after standard care treatment is common new therapies are needed. The targeted alpha therapy with 212Pb-NNV003 presented in this study combines cytotoxic α-particles from 212Pb, the anti-CD37 antibody NNV003, targeting B-cell malignancies. goal was to explore for CD37 positive preclinical mouse models.An anti-proliferative effect observed both (MEC-2) Burkitt's (Daudi) cells vitro. In biodistribution experiments,...
Seven hundred sixty three basal cell carcinomas (BCCs) in 122 patients were treated by photodynamic therapy 5-aminolevulinic acid (ALA) cream topically applied, either alone, combination with dimethyl sulphoxide (DMSO) and ethylenediaminetetraacetic disodium salt (EDTA), or DMSO as a pretreatment. After 3 hours exposure 40 - 200 Joules/cm<sup>2</sup> of 630 nm laser light was given. Fluorescence imaging biopsies showed highly improved ALA penetration depth doubled ALA-induced porphyrin...
The aim of the current study was to investigate therapeutic effect 227Th-radioimmunotherapy on intraperitoneally growing human bioluminescent HER2 positive ovarian cancer cells.In vitro toxicity 227Th-trastuzumab in SKOV3-luc-D3 cells assessed a growth assay. biodistribution administrated athymic nude mice without tumor determined. For vivo therapy, seventy female were inoculated with 17 days prior injection single doses 1000 kBq/kg, 600 kBq/kg or 400 three injections separated by 4 weeks....
Current preclinical dosimetric models often fail to take account of the complex nature absorbed dose distribution typical in vitro clonogenic experiments targeted radionuclide therapy. For this reason, survival is expressed as a function added activity rather than delivered cells/cell nuclei. We designed multi-cellular dosimetry model that takes into realistic distributions cells Petri dish, for establishment curves dose. General-purpose software tools were used generation realistic,...
Abstract Some patients with B-cell non-Hodkin lymphoma Lymphoma (NHL) become refractory to rituximab (anti-CD20 antibody) therapy associated chemotherapy. Here, the effect of anti-CD37 antibody-radionuclide conjugate lutetium-177 ( 177 Lu)-lilotomab (Betalutin ® ) was investigated in preclinical models NHL. In SCID mice bearing DOHH2 (transformed follicular lymphoma, FL) cell xenografts, Lu-lilotomab significantly delayed tumor growth, even at low activity (100 MBq/kg). athymic OCI-Ly8...
The aim of the present study was to compare biodistribution, normal tissue toxicity and therapeutic effect alpha-particle emitting 227Th-trastuzumab beta-particle 177Lu-trastuzumab in mice with HER2- expressing SKBR-3 breast cancer xenografts.Biodistributions two radioimmunoconjugates were determined at different time points after i.v. injection. Inhibition tumor growth measured single injection (200, 400, 600 or 1000 kBq/kg), (40 200 MBq/kg) saline. profiles compared by measurements body...
The aim of this study was to explore the β-emitting lutetium-177 labelled anti-CD37 antibody NNV003 (177Lu-NNV003, Humalutin®) for treatment non-Hodgkin's lymphoma in vitro studies and animal models. Cytotoxicity 177Lu-NNV003 measured REC-1 (mantle cell lymphoma) DOHH-2 (diffuse large B lines. Biodistribution studied mice bearing subcutaneous or MEC-2 (chronic lymphocytic leukaemia) xenografts. therapeutic effect a single injection intravenously subcutaneously injected with cells....
Abstract [ 177 Lu]Lu-DOTA-NNV003, a radioimmunoconjugate targeting CD37, is developed as novel radioimmunotherapy (RIT) treatment for patients with B cell non-Hodgkin’s lymphoma (NHL). Since are at risk developing hematological toxicities due to CD37 expression on normal cells, we aimed develop 89 Zr-labeled NNV003 positron emission tomography (PET) imaging surrogate tool predict Lu]Lu-DOTA-NNV003 RIT whole-body distribution and tumor uptake. antibody was first radiolabeled Zr. Zr]Zr- N...
Background and purpose PARP inhibitors have been shown to increase the efficacy of radiotherapy in preclinical models. Radioimmunotherapy results selective radiation cytotoxicity targeted tumour cells. Here we investigate combined effect anti-CD37 β-emitting 177 Lu-NNV003 radioimmunotherapy inhibitor olaparib, gene expression profiles CD37 positive non-Hodgkin’s lymphoma cell lines. Materials methods The olaparib was studied seven lines using a fixed-ratio ray design, combination index...
Photodynamic therapy has been used for treatment of malignant cutaneous lesions. Photosensitizer topically applied, 5-aminolevulinic acid, with light delivered at 630 nm. A study response rate to varying doses was performed, it might seem that 40 - 50 J/cm<SUP>2</SUP> is sufficient superficial For nodular lesions higher are needed. Some patients tumors in the gastrointestinal tract have treated systemic administration acid and re-treated Photofrin case unsatisfactory results. From...
An ordinary fluorescence spectrometer equipped with a dichroic mirror and fiber optics can be used to measure sensitizer in tumors normal tissues. Our findings such an instrument showed that after oral administration of 60 mg/kg 5-aminolevulinic acid (ALA) mucosas rectal adenomas fluoresced stronger than skin. Also basal cell carcinomas (BCCs) porphyrin skin topical application ALA. The BCCs decayed rapidly during standard laser irradiation at 630 nm. degradation rate porphyrins the tumor...
Lutetium (177Lu) lilotomab satetraxetan (177Lu-lilotomab) is a novel anti-CD37 radioimmunoconjugate (RIC) currently in Phase 2b clinical trial for treatment of non-Hodgkin lymphoma (NHL). The aim the current study was to investigate tolerability and anti-tumor efficacy multiple dosing 177Lu-lilotomab vivo. Nude mice with subcutaneous (s.c.) NHL (Ramos) xenografts were given 2, 3 or 4 weekly injections 300 MBq/kg NaCl. Treatment assessed by body weight, hematology histopathological...
Abstract Introduction: CD37 has shown promise as a new therapeutic target for B-cell malignancies. is highly and selectively expressed on the surface of mature B lymphocytes Alpha-emitting radionuclides have demonstrated potential cancer targeted therapies because efficient energy deposition along short alpha track (50-100 µm) causing localized irreparable DNA damage while sparing surrounding healthy tissues. We developed therapy (TAT) where CD37-specific antibody NNV003 coupled to...
Nine patients with malignant pleural mesothelioma underwent extensive surgery followed by intra-operative photodynamic therapy. Two mg/kg Photofrin was given 48 hours prior to surgery. The thoracic cavity and eventual remaining lung were exposed 15 - 30 Joules/cm<sup>2</sup> of 630 nm laser light. Tumor tissue analyzed microscopic photometrical techniques. Five mixed or epithelioid tumors fluorescence intensity > 100 gray level/pixel seemed benefit from the One patient free disease 18...
Abstract There is an unmet medical need for new therapeutic approaches and targets patients with non- Hodgkin lymphoma (NHL) who relapse or are refractory to anti-CD20 immunotherapy. Therefore, we developed a humanized IgG 1 antibody targeting CD37, which was tailored be afucosylated enhanced antibody-dependent cellular cytotoxicity (ADCC) (NNV024). In line this, NNV024 induced three-fold more potent ADCC activity against patient-derived chronic lymphocytic leukemia (CLL) cells compared...
Abstract The aim of this study was to evaluate the cytotoxic and anti-tumor efficacy beta-emitting lutetium labelled NNV003 antibody (177Lu-NNV003) in non-Hodgkin lymphoma (NHL) Chronic Lymphocytic Leukemia (CLL) models. Antibody-Dependent Cellular Cytotoxicity (ADCC) Complement-Dependent (CDC) were measured REC-1 (MCL), MEC-2 DOHH-2 (DLBCL) cells using FcRγIIIa immortalized NK92 as effector cells. Phagocytosis (ADCP) a commercially available FcRγIIa-H reporter kit. Binding internalization...